Circulating Neuregulin-1 and Chronic Heart Failure with Preserved Ejection].

Kardiologiia 2020 Dec 15

filter terms:

Chronic heart failure (CHF) with preserved ejection fraction (CHFpEF) is an unsolved, socially relevant challenge since it is associated with a high level of morbidity and mortality. Early markers for this pathology are unavailable, and therapeutic approaches are undeveloped. This necessitates extensive studying the mechanisms of CHFpEF to identify therapeutic targets. According to current notions, systemic inflammation and endothelial dysfunction play an important role in the pathogenesis of CHFpEF. These processes induce the development of myocardial fibrosis and impairment of cardiomyocyte relaxation, thereby resulting in diastolic dysfunction and increased left ventricular (LV) filling pressure. Neuregulin-1 (NRG-1) is a paracrine growth factor and a natural agonist of ErbB receptor family synthesized in the endothelium of coronary microvessels. The NRG-1 / ErbB4 system of the heart is activated at early stages of CHFpEF to enhance the cardiomyocyte resistance to oxidative stress. Preclinical and clinical (phases II and III) studies have shown that the recombinant NRG-1 therapy results in improvement of myocardial contractility and in LV reverse remodeling. Results of recent studies suggest possible anti-inflammatory and antifibrotic effects of NRG-1, which warrants studying the activity of this system in patients with CHFpEF.

Citation

A A Shchendrigina, K A Zhbanov, E V Privalova, A O Iusupova, A H Bytdaeva, Yu A Danilogorskaya, E A Zheleznykh, A Yu Suvorov, V Yu Zektser, M G Mnatsakanyan, O V Lyapidevskaya, N V Khabarova, Yu I Naymann, Yu N Belenkov, E S Starostina. Circulating Neuregulin-1 and Chronic Heart Failure with Preserved Ejection]. Kardiologiia. 2020 Dec 15;60(11):1222